Navigation Links
Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008
Date:1/31/2008

UNION CITY, Calif., Jan. 22 /PRNewswire-FirstCall/ -- Abaxis, Inc. (Nasdaq: ABAX), a medical products company manufacturing point-of-care blood analysis systems, has scheduled a conference call to discuss its financial results for the third quarter of fiscal year 2008, ended December 31, 2007. The call will be at 4:15 p.m. ET, Thursday, January 31, 2008.

Participants can dial (877) 356-5706 or (706) 643-0580 to access the conference call, or can listen via a live Internet web cast, which can be found at http://www.abaxis.com. A replay of the call is available by visiting http://www.abaxis.com for the next 30 days or by calling (800) 642-1687 or (706) 645-9291, access code 32155678, through February 2, 2008.

About Abaxis

Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

Contact: Clint Severson Lytham Partners, LLC

Chief Executive Officer Joe Dorame, Joe Diaz & Robert Blum

Abaxis, Inc.
'/>"/>

SOURCE Abaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Abaxis to Present at the Sidoti & Company Sixth Annual San Francisco Institutional Investor Forum Conference
2. Abaxis CEO Clint Severson Named Entrepreneur of the Year by Forbes Magazine
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. QMed, Inc. Reports July Medicare SNP Enrollments
5. Phlo Affiliate Reports Expanded Coverage to Oregon Border
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/3/2008)...nal Pipeline Product Agreement Executed to Support... MONTREAL and BAGSVAERD, Denmark, Dec. 3 /PRNewswi...X:CJB) and Novozymes Biopharma UK Ltd., a subsidia... the Companies have entered into a long-term Manuf...iopharma will exclusively supply its recombinant h...
(Date:12/3/2008)...c. 3 CeloNova BioSciences, Inc., a...which it is commercializing the,CATANIA(TM) Coron...stent,system that has not had any stent thrombosi...ble for purchase throughout Europe and now some Mi... expansion ongoing. Concurrently,CeloNova notes ...
(Date:12/3/2008)... Advanced Life Sciences ... that the U.S. Food and Drug,Administration (FDA)...lication,(NDA) for cethromycin, a novel once-a-da...oderate community acquired pneumonia (CAP). The F...review such that the anticipated,target action da...
(Date:12/3/2008)... , , CALGARY, Dec. 3 /PRNewswire-FirstCall/...ogy company developing protein pharmaceuticals in ... a phase I/II clinical trial of its plant-produced...umans. The trial, taking place in the United Kingd...in a three-arm study (SBS-1000 insulin and two com...
Breaking Biology Technology:ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 2ConjuChem and Novozymes Enter Long-Term Supply Agreement for Recombumin(R) use in PC-DAC(TM):Exendin-4 3CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 2CeloNova BioSciences Commercializes CATANIA(TM) Coronary Stent With NanoThin Polyzene(R)-F in Europe and Middle East 3Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia 2Advanced Life Sciences Announces Cethromycin NDA Accepted for Filing by FDA for the Treatment of Community Acquired Pneumonia 3SemBioSys begins phase I/II trial of insulin produced in plant seeds 2SemBioSys begins phase I/II trial of insulin produced in plant seeds 3
... Inc. , a Madison-based media solutions company, a...ave for the first time exceeded $1 million in sale...as taken in growth strategies, having increased it...dicator that the company is expected to be profita... tripled to $1.2 million, compared $343,000 for th...
...New York Times by Giuliano Hazan, a cooking instru...In it, he draws an intriguing contrast between how...llow versus Americans. I was born and raised in th... I can appreciate both sides of this national divi...he difference between American and Italian percept...
...ites to provide them with health maintenance infor...the University of Wisconsin-Milwaukee . And Milwa...the subject of the study, which aims to examine th...eb sites and what influences people to trust the i...isions. The company was selected based on their eC...
...c recorders, digital cameras and laptops served as...uisition of ID Technologies Pte Ltd. ID Technologi...of pressure sensitive die-cut components and label... Asia-Pacific Allan Klotsche, this acquisition, al... up a very significant portion of the available ma...
Other Biology Technology:Sonic Foundry tops $1 million in revenue 2You are how you manage 2You are how you manage 3eCare Solutions, UW Milwaukee to study health web sites 2Brady continues growth through Asian acquisition 2
(Date:12/3/2008)..., COLUMBIA, Mo. "FORE"...Though they may not hel... might change the way golfers think about the loca... University of Missouri study. , "There are more...d approximately 70 percent of that land is not use...essor of Biology in the MU College of Arts and Sci...
(Date:12/3/2008)..., MADISON, WI, DECEMBER 1, 2008 -- As the United ...hods and push towards energy independence, cellulo...ommercially viable technologies. Corn stover remai... of soil organic carbon (SOC) associated with the ...dstock is of agricultural and environmental concer...
(Date:12/3/2008)..., The widespread problem of children failing to t...ng illnesses is to be tackled as part of a new uni...nvolving health specialists at The University of N...w on the experiences of school children with asthm... to learn about the barriers that prevent them fro...
(Date:12/3/2008)..., A multi-institution team of investigators led b...e University of Southern California (USC) has rece...itutes of Mental Health (NIMH) for a groundbreakin... thousands of patients in order to study the genet..., The USC Center for Genomic Psychiatry and Mass...
Breaking Biology News(10 mins):Golf course: Playing fields, wildlife sanctuaries or both 2Managing carbon loss 2A spoonful of sugar? 2A spoonful of sugar? 3USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 2USC researchers head global effort to study genetic risks that contribute to psychiatric diseases 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG GCSF 1151 1Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG GCSF 1151 2Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG GCSF 1151 3Maxygen Announces Positive Progress in Phase IIa Clinical Trial of Novel PEG GCSF 1151 4Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug 1147 1Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug 1147 2U Mass Medical School and Carnegie announce licensing agreements with Oxford BioMedica 1793 1U Mass Medical School and Carnegie announce licensing agreements with Oxford BioMedica 1793 2Pollution shrinks fetus size 3A Brisbane study finds 9141 1Pollution shrinks fetus size 3A Brisbane study finds 9141 2
...rn Australian researchers have discovered a new ge...prostate cancer, as well as diabetes. , The gene, ...ern Australian Institute for Medical Research,s (W...ssor Peter Leedman, in collaboration with Professo...ne in Texas. , "When we baited our hook and went ...
...rchers from Delft University of Technology,s Kavli...se the motors of biological cells in extremely sma... transport system that uses electrical charges to ...this, the Delft researchers sorted the individual ... of the University of Florida has called the Delft...
...m of researchers working at the University of Bris...iosis, a deadly form of food poisoning. Their work...by Professor Jose Vazquez-Boland, has shown that o...isteria in the body, despite it being ineffective ...fective in the laboratory, this drug has never bee...
...week Scientists of the Alfred Wegener Institute fo...ir pollution on record since measurements began in...splayed significantly increased aerosol concentrat...rom eastern Europe have been transported into the ...weather situation. , Usually the air is pure and ...
Other Biology News:Gene discovery opens door to tackling disease 2Biological motors sort molecules one by one on a chip 2Record air pollution above the Arctic 2